- Home
- GERN vs NMIH Comparison
GERN vs NMIH Comparison
Compare GERN & NMIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- NMIH
- Stock Information
- Founded
- GERN 1990
- NMIH 2011
- Country
- GERN United States
- NMIH United States
- Employees
- GERN N/A
- NMIH N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- NMIH Property-Casualty Insurers
- Sector
- GERN Health Care
- NMIH Finance
- Exchange
- GERN Nasdaq
- NMIH Nasdaq
- Market Cap
- GERN 2.5B
- NMIH 2.9B
- IPO Year
- GERN 1996
- NMIH 2013
- Fundamental
- Price
- GERN $2.89
- NMIH $37.72
- Analyst Decision
- GERN Strong Buy
- NMIH Buy
- Analyst Count
- GERN 10
- NMIH 7
- Target Price
- GERN $7.15
- NMIH $42.00
- AVG Volume (30 Days)
- GERN 14.8M
- NMIH 491.0K
- Earning Date
- GERN 02-26-2025
- NMIH 02-12-2025
- Dividend Yield
- GERN N/A
- NMIH N/A
- EPS Growth
- GERN N/A
- NMIH 18.41
- EPS
- GERN N/A
- NMIH 4.37
- Revenue
- GERN $29,480,000.00
- NMIH $635,847,000.00
- Revenue This Year
- GERN $31,478.06
- NMIH N/A
- Revenue Next Year
- GERN $290.89
- NMIH $7.18
- P/E Ratio
- GERN N/A
- NMIH $8.63
- Revenue Growth
- GERN 9199.68
- NMIH 13.40
- 52 Week Low
- GERN $1.64
- NMIH $28.73
- 52 Week High
- GERN $5.34
- NMIH $42.49
- Technical
- Relative Strength Index (RSI)
- GERN 25.84
- NMIH 56.36
- Support Level
- GERN $2.80
- NMIH $34.52
- Resistance Level
- GERN $3.68
- NMIH $37.31
- Average True Range (ATR)
- GERN 0.18
- NMIH 0.73
- MACD
- GERN -0.04
- NMIH 0.23
- Stochastic Oscillator
- GERN 10.23
- NMIH 94.96
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About NMIH NMI Holdings Inc.
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.